A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Trial of X4P-001 in Patients With WHIM (Warts, Hypogammaglobulinemia, Infections and Myelokathexis) Syndrome

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Trial of X4P-001 in Patients With WHIM (Warts, Hypogammaglobulinemia, Infections and Myelokathexis) Syndrome

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 11 Dec 2017

At a glance

  • Drugs X4P 001 (Primary)
  • Indications WHIM syndrome
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms X4P-001-MKKA
  • Sponsors X4 Pharmaceuticals
  • Most Recent Events

    • 11 Dec 2017 According to a X4 Pharmaceuticals media release, Dr. David C. Dale, MD is the lead investigator of this study.
    • 11 Dec 2017 According to a X4 Pharmaceuticals media release, preliminary results for first 5 patients from the open label phase 2 portion of the this study were presented at the 59th Annual Meeting of the American Society for Hematology (ASH) on 9th December 2017.
    • 16 Nov 2017 According to a X4 Pharmaceuticals media release, first clinical data from this trial will be presented at the 59th Annual Meeting of the American Society for Hematology (ASH) 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top